BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

But it's the Pfizer case that seems to me to be a more important harbinger of the challenges companies may face as they try to encourage diversity and inclusion in the workplace.

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

Oct 3 (Reuters) - An advocacy group that opposes diversity initiatives in medicine urged a federal appeals court on Tuesday to revive its lawsuit claiming a fellowship program offered by Pfizer ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer said its Wyeth unit has agreed to pay a $784.6 million settlement for cases related to the calculation of Medicaid rebates for a gastric drug sold between 2001 and 2006, according to Reuters.

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout. By Gabrielle Masson Oct 8, 2024 4:58pm. Pfizer ReViral RSV R&D. In another blow to its $525 million ...

Aug 28 (Reuters) - Pfizer PFE.N and BioNTech 22UAy.DE asked a U.S. government tribunal on Monday to cancel patents on COVID-19 vaccine technology that rival Moderna MRNA.O has accused the ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read more here.